Novo Nordisk A/S (NYSE:NVO) is Traynor Capital Management Inc.’s 7th Largest Position

Traynor Capital Management Inc. raised its position in shares of Novo Nordisk A/S (NYSE:NVO) by 10.9% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 217,682 shares of the company’s stock after buying an additional 21,356 shares during the period. Novo Nordisk A/S comprises about 2.3% of Traynor Capital Management Inc.’s investment portfolio, making the stock its 7th biggest holding. Traynor Capital Management Inc.’s holdings in Novo Nordisk A/S were worth $22,519,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Pacific Center for Financial Services lifted its position in shares of Novo Nordisk A/S by 100.0% in the 3rd quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock worth $25,000 after purchasing an additional 135 shares during the period. Copeland Capital Management LLC lifted its position in shares of Novo Nordisk A/S by 100.0% in the 3rd quarter. Copeland Capital Management LLC now owns 282 shares of the company’s stock worth $26,000 after purchasing an additional 141 shares during the period. Bell Investment Advisors Inc increased its stake in shares of Novo Nordisk A/S by 79.9% in the 3rd quarter. Bell Investment Advisors Inc now owns 286 shares of the company’s stock worth $26,000 after acquiring an additional 127 shares in the last quarter. Citizens National Bank Trust Department increased its stake in shares of Novo Nordisk A/S by 100.0% in the 3rd quarter. Citizens National Bank Trust Department now owns 300 shares of the company’s stock worth $27,000 after acquiring an additional 150 shares in the last quarter. Finally, Tyler Stone Wealth Management increased its stake in shares of Novo Nordisk A/S by 100.0% in the 3rd quarter. Tyler Stone Wealth Management now owns 292 shares of the company’s stock worth $27,000 after acquiring an additional 146 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

Shares of NVO stock traded up $0.35 during trading hours on Thursday, reaching $128.40. The company had a trading volume of 3,651,900 shares, compared to its average volume of 5,233,031. The business has a fifty day moving average price of $121.76 and a 200-day moving average price of $104.38. Novo Nordisk A/S has a one year low of $75.56 and a one year high of $138.28. The firm has a market cap of $576.20 billion, a PE ratio of 47.54, a price-to-earnings-growth ratio of 2.13 and a beta of 0.41. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.64 and a current ratio of 0.82.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, January 31st. The company reported $0.71 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.05. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. The firm had revenue of $9.51 billion during the quarter, compared to analyst estimates of $9.14 billion. Sell-side analysts predict that Novo Nordisk A/S will post 3.35 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently disclosed a Semi-Annual dividend, which will be paid on Tuesday, April 2nd. Investors of record on Monday, March 25th will be issued a $0.664 dividend. This is an increase from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. The ex-dividend date is Friday, March 22nd. This represents a dividend yield of 0.9%. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 49.17%.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on NVO shares. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 price target for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, March 20th. UBS Group initiated coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 16th. They set a “neutral” rating for the company. Finally, TD Cowen raised their price objective on shares of Novo Nordisk A/S from $105.00 to $115.00 and gave the company an “outperform” rating in a research note on Monday, December 4th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $126.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.